)

SWK Holdings (SWKH) investor relations material
SWK Holdings Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Monetized the majority of royalty assets and MOD3 subsidiary assets, using proceeds for a $4.00 per share special dividend and simplifying operations to focus on specialty finance and life science lending.
Q2 2025 GAAP net income was $3.5M, down from $3.7M in Q2 2024; adjusted non-GAAP net income rose to $4.6M from $2.6M year-over-year.
Returned $49M to shareholders via special dividend and $3M through repurchase of 198,162 shares year to date.
The company operates two segments: Finance Receivables and Pharmaceutical Development, with a strategic shift toward specialty finance after asset sales.
Remaining assets include $234M in gross performing first lien term loans (14.1% yield), $12M in non-performing royalties, $5M in public equity warrants, and 11 private warrants/earn-outs carried at $0 for GAAP.
Financial highlights
Q2 2025 revenue was $10.1M, down from $10.8M in Q2 2024, mainly due to the royalty portfolio sale; six-month revenue was $21.9M, slightly down year-over-year.
Net income for Q2 2025 was $3.5M; for the six months ended June 30, 2025, net income was $8.1M, up from $4.1M in the prior year period.
Operating expenses dropped to $5.4M from $9.9M year-over-year, with significant declines in Mod Three and finance receivables segment expenses.
Allowance for credit losses decreased to $8.8M from $11.2M at year-end, with Q2 2025 provision for credit losses at $0.8M, down from $4.1M in Q2 2024.
Cash and cash equivalents increased to $8.0M as of June 30, 2025, from $5.9M at year-end 2024.
Outlook and guidance
Management expects finance receivables and marketable investments to generate positive cash flows for the remainder of 2025.
Normalized SG&A expected to be around $2M per quarter, barring one-off legal expenses.
Management remains focused on financing innovative life science companies and supporting existing performing borrowers.
Next SWK Holdings earnings date

Next SWK Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
At the Intersection of Finance and Healthcare
SWK Holdings Corporation is an American finance company that primarily operates within the healthcare sector, with a focus on life sciences and pharmaceuticals. Given the capital-intensive nature of healthcare innovations, SWK Holdings provides financial support and investments to initiatives in the sector. The company offers customized financing solutions tailored to support companies in various stages of research, development, and commercialization.
Texas Made
SWK Holdings was founded in 1996 and is headquartered in Dallas, Texas. The company operates in two different segments: Life Science Specialty Finance and Enteris BioPharma, which are both centered on SWK’s core focus on monetizing revenue streams and intellectual property within the life sciences sector. The company's approach is centered on understanding the specific needs of healthcare and biotech enterprises, offering financial structures that facilitate growth and advancement. Given the complex nature of the industry, having the right expertise and experience is absolutely paramount to achieving the best possible results. Some companies that SWK has worked closely with include Aziyo, Biolase, and Eton Pharmaceuticals.
Life Science Specialty Finance
Recognizing the unique financial challenges companies in life sciences face, particularly when it comes to drug development and medical innovation, SWK provides tailored financing solutions. These are designed to address the capital-intensive nature of research, clinical trials, and product commercialization. Through its specialty finance operations, SWK extends secured loans to smaller life science companies, bridging funding gaps and ensuring the continuity of research. In return, SWK typically benefits from interest and fees, as well as royalties from successfully commercialized products.
Enteris BioPharma
Enteris BioPharma, a subsidiary of SWK Holdings, is a biotechnology company specializing in developing innovative drug delivery solutions. One of its core technologies is the Peptelligence™ platform, which enables oral delivery of molecules that are traditionally administered through injections.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage